JP Morgan saw key M&A activity, new approaches from key UK pharma, a buzz about cell and gene therapy and concerns about the ongoing impact of the US Government shutdown. I’ve written a short blog on my perspective here.
On Brexit, the vote tomorrow is a key watershed, but for our sector we expect ongoing detail from the government on no-deal contingencies. We will focus our analytical and briefing capability on providing members with actionable information, in what is a very uncertain political context.
Happy New Year everyone. I write this on my way to San Francisco to start the year at the JP Morgan conference. This look ahead to 2019 summarises my key themes for the year and closes with a quick summary of UK news that came out over the holiday period.
Discovery Park - and some of the businesses driving its success - will use one of the UK’s leading science events to showcase why it remains the perfect location for science companies looking to grow and collaborate. It will be attending Genesis 2018 with several of its life sciences tenants, showcasing their activities and discussing its plans for the future development of the Park.
As the Brexit negotiations inch ever closer to a crunch point and debates heat up in Parliament over the UK’s preparedness to leave the EU, the government continues to ready itself to strike future trade deals. This work is being led by Liam Fox’s Department for International Trade (DIT), which was set-up after the EU referendum with the responsibility to lead the UK’s independent trade policy post-Brexit.
This week I am heading to Hong Kong and then Shanghai in China. Hong Kong stock market rules have recently changed making it easier for pre revenue companies to list on its stock market. I am exploring there how we can jointly build the life science analytical capability needed for global liquidity - and make dual listing - or similar - a practical reality for UK companies seeking investment.
The UK BioIndustry Association (BIA) and the Association of the British Pharmaceutical Industry (ABPI) have submitted a joint submission in response to the MHRA and DHSC consultation on no deal contingency legislation for medicines and devices regulation for the UK.
Commenting on the state of the UK life sciences ecosystem in a keynote address to the Bioindustry Association (BIA) UK Bioscience Forum in London BIA CEO Steve Bates OBE, will say: “The UK life sciences ecosystem is in a fantastic place. I see innovation, opportunity and collaboration everywhere. We are in an era of profound scientific opportunity.”
The opening address will cover key issues that are currently having an impact on the UK bioscience ecosystem including government funding, Brexit, R&D development, the NHS and the future of the European Medicines Agency (EMA).
Compliance, regulation and red tape can be burdensome for manufacturers, but should they be viewed more positively? Risk management has the potential to add value and longevity to a product – and to offer an opportunity for growth. Here are reasons why investing in risk management should be a guiding principle for the entire product development cycle, from the initial concept right through to marketing and post-market surveillance:
It was fantastic to see Greg Winter, serial entrepreneur and founder of BIA member Bicycle Therapeutics jointly awarded the Nobel Prize for Chemistry. His ground-breaking work humanising antibodies led to the production of Humira, the best selling prescription drug last year. The Nobel Prize in Physiology or Medicine was awarded jointly to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation. The two breakthroughs together provide the scientific underpinning for the fantastic work our sector has done to translate this science into practical therapies for patients.